Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
MetLife: De-Risking Legacy Liabilities with $10B VA Exit—What’s the Long-Term Impact on Profitability, Interest Rate Sensitivity & Capital Allocation Flexibility?
MetLife’s Q1 FY25 results validated the strength of its New Frontier strategy, with adjusted EPS rising 7% YoY to $1.96, supported by underwriting strength in Group Benefits, where earnings rose 29% and mortality ratios came in favorably at 84.8%. Variable investment income (VII) and stable non-medical health ratios added margin stability, even amid modest FX drag and spread compression in Retirement & Income Solutions. Importantly, the $10B variable annuity transaction with Talcott removed 40% of VA account value, cutting tail risk, avoiding $45M in annual hedging costs, and freeing ~$250M in statutory capital—all while embedding a $6B AUM mandate for MetLife Investment Management (MIM), which aligns with its transition toward capital-light, fee-based growth. MIM’s broader expansion, including the PineBridge deal and Mesirow onboarding, underscores long-term strategic focus on scalable asset management. International performance was mixed—Asia earnings fell 12% but posted 10% sales growth ex-FX, while LatAm and EMEA showed operational resilience. Capital return was robust, with $1.8B returned and a new $3B buyback authorization, supported by $4.5B in holding cash and a 388% RBC ratio. With variable annuity de-risking complete, MIM ramping, and balance sheet flexibility intact, can MetLife now deliver sustained margin expansion and interest-rate-insulated profitability in a more capital-efficient future?
